1448346-63-1

Basic information

• Product Name: AG-120
• Synonyms: AG-120;AG-120 racemic;AG-120 Ivosidenib;Ivosidenib (RG-120);1-(4-Cyano-2-pyridinyl)-5-oxo-L-prolyl-2-(2-chlorophenyl)-N-(3,3-difluorocyclobutyl)-N2-(5-fluoro-3-pyridinyl)glycinamide;(2S)-N-(1 -(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide;Ivosidenib (RG-120 racemic);AG-120 Racemate
• CAS NO: 1448346-63-1
• Molecular Formula: C₂₈H₂₂ClF₃N₆O₃
• Molecular Weight: 582.9608896
• EINECS: -0
• Mol File: 1448346-63-1.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 854.3±65.0 °C(Predicted)
• Appearance: /
• Density: 1.51±0.1 g/cm3(Predicted)
• PKA: 11.58±0.40(Predicted)
• CAS DataBase Reference: AG-120(CAS DataBase Reference)
• NIST Chemistry Reference: AG-120(1448346-63-1)
• EPA Substance Registry System: AG-120(1448346-63-1)

Safety Data

• Hazardous Substances Data: 1448346-63-1(Hazardous Substances Data)

Usage

Uses

AG-120 is an intermediate in the preparation of oxoazacyclecarboxamides as anticancer agents.

Upstream product

• 10386-27-3 2-bromoisonicotinonitrile 
• 2070009-31-1 (2S)-N-{(1R)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide 
• 210169-05-4 5-fluoropyridin-3-amine 
• 89-98-5 2-chloro-benzaldehyde 
• 1355328-31-2 1,1-difluoro-3-isocyanocyclobutane 
• 1355328-30-1 N-(3,3-difluorocyclobutyl)formamide 
• 33252-30-1 2-chloro-4-pyridinenitrile 

Downstream Products

• 2070009-31-1 (2S)-N-{(1R)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide 
• 1448347-49-6 (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF (2S)-N-{(1S)-1-(2-CHLOROPHENYL)-2-[(3,3-DIFLUOROCYCLOBUTYL)-AMINO]-2-OXOETHYL}-1-(4-CYANOPYRIDIN-2-YL)-N-(5-FLUOROPYRIDIN-3-YL)-5-OXOPYRROLIDINE-2-CARBOXAMIDE

The present invention relates to improved process for the preparation of (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide and its pharmaceutically acceptable salts represented by the following structural formula. Formula-1 The present invention relates to novel intermediates useful in the preparation of Ivosidenib of formula-1 and novel process for the preparation of (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide. The present invention also relates to solid state forms of (2S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2- oxoethyl}-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide.

SOLID STATE FORMS OF IVOSIDENIB

Solid state forms of Ivosidenib, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.